Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
– ALPN-303 well-tolerated in a Phase 1 healthy volunteer study with on-target effects on key biomarkers, supporting a highly competitive, potentially best in class profile – – Davoceticept (ALPN-202) demonstrates encouraging outcomes, especially in renal cell carcinoma, as monotherapy and in combination with pembrolizumab in ongoing NEON-1 and NEON-2 studies respectively – – Alpine management … [Read more…]
